Products
Izastobart Biosimilar Monoclonal Antibody (C5aR1) for Research
Cat No.: GMP-Bios-INN-1246
Anti-C5AR1/CD88 therapeutic antibody (Pre-made Izastobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Izastobart (development codes HIB210/MOR210) is a monoclonal antibody targeting C5AR1 (complement C5a receptor 1). It is developed by Human Immunology Biosciences, I-MAB Biopharma, and MorphoSys for autoimmune disorders and solid tumors. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1246-1mg | 1mg | 3090 |
| GMP-Bios-INN-1246-10mg | 10mg | |
| GMP-Bios-INN-1246-100mg | 100mg | |
| GMP-Bios-INN-1246-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Izastobart biosimilar, Whole mAb, Anti-C5AR1/CD88 Antibody: Anti-C5aR/C5AR1/CD88/C5a anaphylatoxin chemotactic receptor 1 therapeutic antibody |
| INN Name | Izastobart |
| Target | C5AR1/CD88 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Human Immunology Biosciences; I-MAB Biopharma;MorphoSys |
| Conditions Approved | na |
| Conditions Active | Autoimmune disorders;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
